Using multifrequency MRE to evaluate kidney fibrosis in chronic kidney disease
Multifrequency Renal MR Elastography in Evaluation of Chronic Kidney Diseases: Can Shear Stiffness Evaluate Renal Fibrosis in GFR-normal Patients?
This study is testing a new way to see how much scarring is in the kidneys of people with chronic kidney disease using special MRI scans, to help understand how the disease is progressing.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06202235 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with chronic kidney disease (CKD) to assess kidney fibrosis using multifrequency Magnetic Resonance Elastography (MRE). The study aims to provide a noninvasive method for evaluating the extent of fibrosis, which is crucial for understanding CKD progression and its clinical implications. By analyzing patients at various stages of CKD, the research seeks to enhance the understanding of kidney fibrosis and its relationship to patient outcomes. The study will involve renal MRI scans conducted shortly before kidney biopsies to correlate MRE findings with histopathological results.
Who should consider this trial
Good fit: Ideal candidates include CKD patients aged 18-65 who are hospitalized for renal biopsy and have undergone renal MRI.
Not a fit: Patients with acute exacerbations of CKD, severe claustrophobia, or those who cannot tolerate MRE may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safer, noninvasive method for assessing kidney fibrosis, potentially improving patient management and outcomes in CKD.
How similar studies have performed: While the use of MRE for assessing kidney fibrosis is gaining interest, this specific multifrequency approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: (1) adults with CKD defined according to the 2024 KDIGO guidelines, with either elevated SCr or abnormal proteinuria ; and (2) renal MRI was performed within 7 days of the renal biopsy. Exclusion criteria: (1) genitourinary malignancy, polycystic kidney disease, renal transplantation, or acute renal failure; (2) contraindications for MRI examination; (3) poor image quality; (4) kidney deformity or severe hydronephrosis on MRI; and (5) poorly defined corticomedullary demarcation.
Where this trial is running
Shenyang, Liaoning
- Shengjing Hospital of China Medical University — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: yu shi, MD — Shengjing Hospital
- Study coordinator: yu shi, MD
- Email: 18940259980@163.com
- Phone: 189 4025 9980
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.